{u'keywords': [u'applicant', u'Lilly', u'patent', u'TGA registration', u'gemcitabine hydrochloride', u'EBEWE Pharma', u'Mr Gray', u'Patents Act', u'reasonable prospect', u'gemcitabine hydrochloride powder', u'application', u'PBS listing', u'ADJR Act', u'extension', u'Applicant obtains patent', u'Trade Practices Act', u'Sindan-Pharma Gemcitabine Hydrochloride', u'TGA approval', u'product', u'australian patent', u'gemcitabine ebewe', u'term', u'Dr Schnait', u'Lilly Australia Pty', u'Shilpa product', u'Assa Abloy test', u'Judiciary Act', u'proceeding', u'product Gemcitabine hydrochloride', u'court', u'period', u'Eli Lilly', u'extended term', u'Anti-Viral Patent', u'reasonable possibility', u'GEMCITABINE EBEWE gemcitabine', u'Australian Patent Office', u'decision', u'Concrete Constructions', u'Lilly notes', u'emphasis Lilly', u'Lilly points', u'Official Journal', u'material gemcitabine hydrochloride', u'lower price', u'gemcitabine hydrochloride formulation', u'Australia Act', u'PBS application', u'prejudice meeting'], u'casename': u'Interpharma Pty Ltd v Commissioner of Patents [2008] FCA 1283 (21 August 2008)', u'filename': u'training_data/08_1283.xml'}